Brooks Automation, Inc. Announces GENEWIZ Selected as Genome Characterization Center by the National Cancer Institute
January 12, 2021 at 04:05 pm
Share
Brooks Automation, Inc. announced that GENEWIZ, the Company's genomics analysis business, has been awarded one of six Genome Characterization Center Indefinite Delivery Indefinite Quantity (IDIQ) contracts from the National Cancer Institute (NCI). The NCI, the nation's leader in cancer research and part of the National Institutes of Health (NIH), chose GENEWIZ to provide whole exome sequencing to new research projects at its Center for Cancer Genomics for a period of three years. GENEWIZ will generate data from DNA samples received from the Biospecimen Core Resource and send raw sequencing data, associated metadata, and other characterization data to the Genomic Data Commons. This data will then be shared with the Genomic Data Analysis Network and research community.
Azenta, Inc. is a provider of biological and chemical compound sample exploration and management solutions for the life sciences industry. The Companyâs segments include Sample Management Solutions, Multiomics and B Medical Systems. The Sample Management Solutions segment offers end-to-end sample management products and services, including sample and repository services and core products (automated stores, cryogenic systems, automated sample tube, and consumables and instruments). The Multiomics segment provides genomic and other sample analysis services, including gene sequencing and gene synthesis. B Medical Systems segment is focused on the manufacturing and distribution of temperature-controlled storage and transportation solutions in international markets to governments, health institutions, and non-government organizations. It provides products and services through its brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, Barkey, and B Medical Systems.